Results 141 to 150 of about 5,788 (178)

Efficacy of Sofosbuvir-Velpatasvir-Ribavirin Regimen for Retreatment of Chronic Hepatitis C in Patients With Prior DAA Failure: A Retrospective Study From a National Treatment Center. [PDF]

Int J Hepatol
Singh S, Sengupta S, Kumar D, Mukherjee K, Hasan AMD, Sadhukhan P, Ahammed SM.   +6 more
europepmc   +1 more source

Newly Proposed Dose of Daclatasvir to Prevent Lethal SARS-CoV-2 Infection in Human Transgenic ACE-2 Mice. [PDF]

Viruses
Mattos M, Sacramento CQ, Ferreira AC, Fintelman-Rodrigues N, Pereira-Dutra FS, de Freitas CS, Gesto JSM, Temerozo JR, Silva APDD, Moreira MTG, Silva RSC, Silveira GPE, Pinto DP, Pereira HM, Fonseca LB, Alves Ferreira M, Blanco C, Viola JPB, Bou-Habib DC, Bozza PT, Souza TML.   +20 more
europepmc   +1 more source

Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries. [PDF]

BMJ Open Gastroenterol
Mustafa A, Davlidova S, Abidi SH, Begimbetova D, Heimer R, Vermund SH, Ali S.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Daclatasvir

Annals of Pharmacotherapy, 2016
Michael A Smith, Rima A Mohammad, Randolph E Regal   +2 more
exaly   +2 more sources

Isothermal Titration Calorimetry and Molecular Modeling Study of the Complex Formation of Daclatasvir by γ-Cyclodextrin and Trimethyl-β-Cyclodextrin

Carbohydrate Polymers, 2023
International audienceThe complex formation between daclatasvir and γ-CD or heptakis(2,3,6-tri-O-methyl)-β-CD (TM-β-CD) was studied by isothermal titration calorimetry and molecular modeling.
David Landy, Alessandro Dessì, Antonio Salgado   +2 more
exaly   +2 more sources

The Impact of Sofosbuvir/Daclatasvir or Ribavirin in Patients With Severe COVID-19 [PDF]

Journal of Antimicrobial Chemotherapy, 2020
OBJECTIVES: Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2.
Anahita Sadeghi, Mahboobeh Momtazan, Andrew M Hill   +2 more
exaly   +2 more sources

Daclatasvir Plus Sofosbuvir, With or Without Ribavirin, for Hepatitis C Virus Genotype 3 in a French Early Access Programme

Liver International, 2017
International audienceBACKGROUND & AIMS:Optimally effective treatment for hepatitis C virus genotype 3 (GT3) is urgently needed, particularly in advanced liver disease. Daclatasvir plus sofosbuvir was efficacious in phase 3 studies.
Hélène Fontaine, Isabelle Rosa, Eric Nguyen-Khac   +2 more
exaly   +2 more sources

Sofosbuvir Plus Daclatasvir for Post-Transplant Recurrent Hepatitis C: Potent Antiviral Activity but No Clinical Benefit If Treatment Is Given Late

Digestive and Liver Disease, 2014
We evaluated efficacy and safety of sofosbuvir and daclatasvir±ribavirin in liver transplant recipients with severe recurrent hepatitis ...
Marzia Montalbano, Peter Ferenci, Raffaella Lionetti   +2 more
exaly   +2 more sources

A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019

New Microbes and New Infections, 2021
Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae ...
R. Dowran, Shabani, M., Sadegh Ehdaei, B., F. Fathi, Fathi, F., Dowran, R., B. Sadegh Ehdaei, M. Shabani   +7 more
exaly   +2 more sources